(Metformin + sitagliptin hydrochloride) is under clinical development by GL Pharm Tech and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Metformin + sitagliptin hydrochloride)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Metformin + sitagliptin hydrochloride) overview
GLH-1SM is under development for the treatment of type 2 diabetes. The drug candidate is a fixed dose combination of metformin and sitagliptin hydrochloride. It is an incrementally modified drug administered as a oral tablet. Metformin acts by targeting AMP-activated protein kinase (AMPK) and sitagliptin hydrochloride acts by targeting dipeptidyl-peptidase (DPP-4).
See Also:
GL Pharm Tech overview
GL Pharm Tech (GLPHarmTech) is a pharmaceutical company that offers drug formulations and delivery technologies. The company offers modified drugs and generic drugs. It offers products under the brands G-SOREN, Olmetec, Lipitor, Caduet, Splendi, Zanidip and Cozaar, among others. GLPHarmTech’s products are used in the treatment of various therapeutic areas which include melasma, diabetes, emergency contraceptive, birth control, endometriosis, hypertension, benign prostatic hyperplasia (BPH) and hormone replacement therapy (HRT), among others. The company works in collaboration with domestic and foreign pharmaceutical companies. It markets products through its partners and distributors. GLPHarmTech is headquartered in Seongnam, South Korea.
For a complete picture of (Metformin + sitagliptin hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
